News and Trends 19 Aug 2014
GSK abandon its joint drug project with Galapagos
According to Reuters, Galapagos, a Belgian biotech group announced that GlaxoSmithKline has stopped a joint drug development project over concerns about adverse effects. In June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines. This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical Proof of Concept. […]